<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Enteric glia activation has been reported to amplify <z:mp ids='MP_0001858'>intestinal inflammation</z:mp> via the enteroglial-specific S100B protein </plain></SENT>
<SENT sid="1" pm="."><plain>This neurotrophin promotes macrophage recruitment in the mucosa, amplify colonic <z:mp ids='MP_0001845'>inflammation</z:mp> and interacts with toll-like receptors (TLR) </plain></SENT>
<SENT sid="2" pm="."><plain>Molecules inhibiting S100B-driven enteric activation might mitigate the course of <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC) </plain></SENT>
<SENT sid="3" pm="."><plain>This study aims to investigate the effects of palmitoylethanolammide (PEA), a drug able to counteract astroglial activation in the central <z:mp ids='MP_0008912'>nervous</z:mp> system, on <z:mp ids='MP_0001858'>intestinal inflammation</z:mp>, in humans and mice </plain></SENT>
<SENT sid="4" pm="."><plain>DESIGN: Mouse models of <z:chebi fb="0" ids="52071">dextran</z:chebi> <z:chebi fb="9" ids="32149">sodium sulphate</z:chebi> (DSS)-induced <z:hpo ids='HP_0002583'>colitis</z:hpo>, colonic biopsies deriving from UC patients and primary cultures of mouse and human enteric glial cells (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EGC</z:e>), have been used to assess the effects of PEA, alone or in the presence of specific PPARα or PPARγ <z:chebi fb="68" ids="48706">antagonists</z:chebi>, on: macroscopic signs of UC (DAI score, colon length, spleen weight, macrophages/neutrophils infiltration); the expression and release of proinflammatory markers typical of UC; TLR pathway in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EGCs</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: PEA treatment improves <z:hpo ids='HP_0000001'>all</z:hpo> macroscopic signs of UC and decreases the expression and release of <z:hpo ids='HP_0000001'>all</z:hpo> the proinflammatory markers tested </plain></SENT>
<SENT sid="6" pm="."><plain>PEA anti-inflammatory effects are mediated by the selective targeting of the S100B/TLR4 axis on ECG, causing a downstream inhibition of nuclear factor kappa B (NF-kB)-dependent <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="68" ids="48706">Antagonists</z:chebi> at PPARα, but not PPARγ, abolished PEA effects, in mice and in humans </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Because of its lack of toxicity, its ability in reducing <z:mp ids='MP_0001845'>inflammation</z:mp> and its selective PPARα action, PEA might be an innovative molecule to broaden pharmacological strategies against UC </plain></SENT>
</text></document>